SUBSCRIBE
SUBSCRIBE
News   Drug Development

Novartis AG/Incyte Corporation Drug Said to Ease Blood-Cancer Symptoms

September 16, 2010 | 
1 min read
NEW YORK, Sept 15 (Reuters) - An experimental Novartis AG (NOVN.VX) medicine in an early-stage trial provided marked relief of symptoms to patients with a rare life-threatening blood cancer called myelofibrosis, the drugmaker said on Wednesday.
Clinical research Phase I
Incyte Novartis
MORE ON THIS TOPIC
vector illustration arrows miss the target board, concept of lost in focus, failure, fail, mistake
Neuroscience
Neurocrine’s Valbenazine Fails Phase III Neurodevelopmental Disorder Trial
December 23, 2025
 · 
2 min read
 · 
Nick Paul Taylor
Brussels, Belgium. 21st December 2020. Exterior view of Pfizer Pharmaceutical company's offices.
Clinical research
Pfizer Reports Patient Death in Long-Term Trial of Hympavzi for Hemophilia A
December 23, 2025
 · 
1 min read
 · 
Annalee Armstrong
Hand holding a lung shape symbol against a blue background. World tuberculosis day, world no tobacco day, lung cancer, pulmonary hypertension, pneumonia
Lung cancer
AstraZeneca’s ATR Inhibitor Fails To Improve Survival in Phase III Lung Cancer Trial
December 22, 2025
 · 
1 min read
 · 
Annalee Armstrong
Upward arrow on the background of the flag of China. Paper plane. Economic recovery. Copy space. Business. Background.
China
AstraZeneca Finds Another Jewel in China With up to $2B For KRAS Inhibitor
December 22, 2025
 · 
1 min read
 · 
Annalee Armstrong